Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Dose Formulation and Compound Handling

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Olao
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Prepare and administer intraperitoneal dose formulations of NCGC00592266, including stability testing, dosing accuracy verification, and handling documentation.

Similar Contracts

Same NAICS industry code

NAICS: 541711
New
Federal
Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

3 days ago

DEADLINE

in 2 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 541690
New
Federal
Pharmacokinetic Data Analysis and ReportingThe contract entails the analysis of plasma concentration-time data to determine pharmacokinetic parameters and generate detailed concentration-time curves, with all results delivered in a structured Excel report accompanied by a narrative summary that interprets the findings. The work is focused on quantitative evaluation of drug behavior in the body, requiring precise computational methods and regulatory-compliant reporting standards to ensure accuracy and reproducibility. The deliverables must be clearly formatted, scientifically sound, and tailored for use in regulatory submissions or internal R&D decision-making. This is a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 541690 indicating specialized scientific and technical consulting services. The opportunity was posted on August 7, 2026, with a response deadline of August 24, 2026, and no set-aside provisions are specified. While the place of performance and point of contact details are not provided, the work is expected to be performed remotely or under flexible arrangements, consistent with the nature of data analysis tasks. The contracting entity is seeking qualified contractors with demonstrated expertise in pharmacokinetic modeling and data reporting to support ongoing research initiatives.
Other Scientific and Technical Consulting Services

POSTED

1 day ago

DEADLINE

in 16 days
View Details